$Viking Therapeutics(VKTX)$ CC的核心点，果然还要剂量爬坡，如果剂量效应还存在的话，bidding war就要开始了，千亿美元的市场，谁不喜欢呢。$礼来(LLY)$ $诺和诺德(NVO)$ Given the promising weight loss signal being reported today, along with the excellent tolerability profile observed thus far, we have decided to pursue further dose escalation in this study and recently commenced dosing in an additional cohort. Decisions on future dose escalation will be made pending a review of the safety and tolerability data generated from completed cohorts. In addition, based on the encouraging trajectory of weight loss observed in this study and the lack of a plateau at 28 days for higher dose cohorts, we believe that further benefits might be anticipated from longer dosing periods and with potentially higher doses. To this end, we have decided to proceed with plans for a Phase II trial in patients with obesity. We plan to initiate this study later this year.